leftspacer middlespacer rightspacer
Media Menu
Featured Material


MAPS BULLETIN
MAPS Bulletin Winter 2013: 2013 Annual Report
 
Media > Ibogaine
February 22, 2012

New Zealand Observational Ibogaine Study for Addiction Approved by Ethics Committee

On February 22, 2012, MAPS’ new observational study of ibogaine treatment for addiction in New Zealand received final approval (pdf) from the Multi-region Ethics Committee. The new study will take place at the Ibogaine Aotearoa Charitable Trust, an independent ibogaine clinic in New Zealand, and will examine the safety and long-term effectiveness of ibogaine treatment for addiction severity and quality of life in 20 to 30 patients. Since this is an observational study, the study requires no further approvals.

Dr. Geoff Noller, Ph.D., the lead investigator for the study, has now begun recruiting subjects. Dr. Noller is delighted at the recent approval of this internationally-funded study which is a new opportunity to collect quality data on an exciting development in the field of addiction treatment, work of which New Zealand is on the cutting edge. Moreover, comparing data with MAPS’ similar well-advanced study in Mexico will offer further insights into appropriate treatment regimes and international best practices regarding ibogaine. The New Zealand study is based in the South Island city of Dunedin, where the research team will work closely with I.ACT, an experienced Dunedin-based ibogaine treatment provider. Other providers throughout the country have also been approached for participation.



Back to Ibogaine Research

Give Our Veterans Hope
1 in 7 Iraq and Afghanistan veterans suffer from PTSD, in many cases leading to suicide. We owe it to our veterans to stop this epidemic.

Tell the Pentagon to fund MAPS' groundbreaking work to treat PTSD.